In 2021, health officials started testing airline passengers who passed through a New York airport to identify imported emerging infectious diseases, part of the U.S. national biosecurity initiative.
Over the past three years, more than 300,000 travelers from over 135 countries have participated each year in the U.S. Centers for Disease Control and Prevention (CDC) Traveler-based Genomic Surveillance (TGS) program.
The TGS has been offering testing services in Los Angeles, Newark, Seattle, Boston, San Francisco, NYC (JFK), and Washington, DC (IAD).
Genomic Surveillance Lands at Chicago and Miami Airports
$57 Million Project To Test Next-Gen Inhaled and Nasal Coronavirus Vaccines
An international team of researchers specializing in human challenge studies has initiated a $57 million project to develop advanced vaccines that can block coronaviruses and prevent infections.
The consortium, consisting of more than a dozen scientific teams and organizations, is led by Imperial College London and co-funded by the European Union's Horizon Europe Programme and CEPI, the Coalition for Epidemic Preparedness Innovations.